AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) and Astellas Pharma Inc. Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS (TivozAnib Use veRsUs Sutent in advanced renal cell carcinoma (RCC): Patient Preference), to establish additional data regarding the investigational drug tivozanib when used as first-line therapy in patients with advanced RCC. The TAURUS study will enroll patients at sites throughout the United States and Western Europe.